Evotec Reports Mixed 2025 Results, Issues Significantly Lower 2026 Guidance Amidst Major Transformation
Summary
Evotec SE announced 2025 financial results at the high end of guidance but provided a significantly reduced outlook for 2026, signaling a transitional year focused on a major operating model transformation.
Key Events
-
2025 Financial Performance
Reported full-year 2025 group revenues of €788.4 million and adjusted group EBITDA of €41.1 million, exceeding prior guidance.
-
Significantly Lower 2026 Guidance
Issued a challenging outlook for 2026, projecting group revenues of €700-780 million and adjusted EBITDA of €0-40 million, a substantial reduction from 2025.
-
Major Operating Model Transformation
Detailed the "Horizon" transformation, aiming for €75 million in structural run-rate cost savings by the end of 2027, with initial financial benefits expected in the second half of 2026.
-
Strategic Milestones & Divestiture
Highlighted several milestone payments from partnerships and reiterated the expected ~$100 million upfront from the Tubulis sale to Gilead Sciences, which was previously announced on April 7, 2026.
Analysis
Evotec SE reported strong 2025 Adjusted EBITDA, exceeding guidance, and highlighted significant milestone payments and the Tubulis divestiture. However, the company issued substantially lower guidance for 2026, projecting a "transition year" with group revenues of €700-780 million and adjusted EBITDA of €0-40 million, a notable decrease from 2025. This challenging short-term outlook is driven by the ongoing "Horizon" operating model transformation, which aims for €75 million in structural cost savings by late 2027 but will impact 2026 profitability. Investors will likely focus on the challenging near-term guidance, despite the long-term strategic benefits of the transformation and positive leadership changes.
At the time of this filing, EVO was trading at $2.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $920.7M. The 52-week trading range was $2.31 to $4.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.